Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine
NCT00056810
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
FED
Sponsor class
Conditions
Guillain-Barre Syndrome
Interventions
DRUG:
4-aminopyridine (4-AP)
Sponsor
FDA Office of Orphan Products Development